Health condition · Clinically reviewed
Kidney cancer, renal cell carcinoma — partial nephrectomy, active surveillance and combination immunotherapy.
Most renal cell carcinomas are detected incidentally on imaging. Small renal masses may be treated with active surveillance; combination immunotherapy has transformed advanced-disease outcomes.
Why trust this guide
- 01
Clinically reviewed
Written by our editorial team and reviewed by a registered UK clinician before publication.
- 02
Sourced, not summarised
Every claim is checked against NICE, EAU or a peer-reviewed source you can see at the end.
- 03
Updated for 2026
Reflects current UK guidance on active surveillance, partial nephrectomy and combination immunotherapy.
Key facts
Kidney cancer at a glance.
The essentials, in plain English — what it is, how it’s usually found, and the treatment options that shape modern UK care.
-
What it is
Renal cell carcinoma is the most common kidney cancer — clear cell is the most common subtype.
-
How it is found
Most cases are detected incidentally on imaging performed for another reason.
-
Small renal masses
Active surveillance is a safe option for small (<4 cm) renal masses, particularly in older adults.
-
Surgery of choice
Partial nephrectomy — preserving kidney tissue — is preferred wherever it is technically feasible.
-
Advanced disease
Combination immunotherapy (ipilimumab + nivolumab, or pembrolizumab + axitinib) is first-line for advanced RCC.
-
Inherited forms
Familial syndromes exist — including von Hippel-Lindau (VHL) and hereditary leiomyomatosis (HLRCC).
Why this guide matters
Not every renal mass needs surgery.
The pathway has changed. Small masses can be watched, partial nephrectomy protects kidney function, and combination immunotherapy has reshaped advanced-disease care.
-
Most cancers are found by accident
Renal cell carcinoma is usually picked up on a scan done for another reason — not from classical symptoms.
-
Kidney-sparing surgery is preferred
Partial nephrectomy protects long-term kidney function, which matters for the heart and for overall health.
-
Combinations lead advanced care
For advanced RCC, first-line treatment is now a combination — either two immunotherapies, or immunotherapy plus a targeted drug.
How the diagnosis is made
From incidental finding to a clear plan.
The pathway UK uro-oncology teams follow, in order — so you know what to expect and why.
Phase 1 · Assessing
Symptoms or incidental finding, then dedicated imaging
Phase 2 · Confirming
Staging imaging and, in selected cases, biopsy
Phase 3 · Planning
Genetic assessment and MDT decision
- 01
Assessing
Symptom or incidental finding
Most renal cell carcinomas are picked up incidentally on imaging done for another reason — symptoms are the exception, not the rule.
- 02
Assessing
CT with contrast (renal-mass protocol)
A dedicated renal-mass CT with contrast is the primary imaging test — it characterises the mass and stages the disease.
- 03
Assessing
MRI if contrast contraindicated
When iodinated contrast can’t be given — poor kidney function or allergy — MRI provides an alternative detailed view.
- 04
Confirming
Chest imaging for metastases
A CT chest is done to look for lung metastases, the most common site of spread from kidney cancer.
- 05
Confirming
Renal mass biopsy (specific cases)
A percutaneous biopsy is used when the diagnosis is uncertain, before ablation, or before systemic therapy for advanced disease.
- 06
Planning
Genetic assessment
Young age, bilateral or multifocal tumours, or a suggestive family history prompts referral for genetic testing.
- 07
Planning
Uro-oncology MDT
A specialist multi-disciplinary team recommends the treatment options that fit the tumour, your kidney function and your preferences.
Typical timeline: 4–8 weeks from imaging finding to a treatment plan.
Symptoms
What kidney cancer actually shows up as.
Most cases are picked up on a scan with no symptoms at all. When symptoms do appear, they matter — here is what to watch for and when to act.
-
Haematuria
Visible blood in the urine — even a single episode — warrants urgent urology assessment.
-
Flank pain
Persistent pain in the side or back below the ribs may reflect a growing renal mass.
-
Palpable mass
A lump felt in the flank or abdomen is a late finding and needs prompt imaging.
-
Weight loss
Unintentional weight loss with fatigue can be the first clue in advanced disease.
-
Anaemia
Unexplained anaemia on routine bloods is a recognised presentation of kidney cancer.
-
Left varicocele
A new left-sided varicocele can indicate a renal-vein tumour thrombus and needs a scan.
-
Hypercalcaemia
A raised calcium as a paraneoplastic effect may be the first laboratory sign.
-
Red flag
Massive haematuria with clot retention — same-day urology assessment.
Treatment
How kidney cancer is treated in the UK.
Treatment is chosen by tumour size, stage, your kidney function and personal preference — from active surveillance to modern surgery and combination immunotherapy.
-
Active surveillance (small masses)
Serial imaging of small renal masses — safe for many older adults, avoiding surgery and its risks.
-
Partial nephrectomy
Removing only the tumour and preserving the rest of the kidney — the preferred surgery where feasible.
-
Radical nephrectomy
Removing the whole kidney — used for larger, central or locally advanced tumours.
-
Percutaneous ablation (RFA, cryo)
Radiofrequency or cryoablation of small tumours through the skin — an option for patients unfit for surgery.
-
Adjuvant pembrolizumab
Immunotherapy after surgery for high-risk RCC to reduce the chance of the cancer coming back.
-
Combination immunotherapy (ipi + nivo)
Ipilimumab plus nivolumab — a first-line combination for intermediate and poor-risk advanced disease.
-
Combination immunotherapy + TKI
Pembrolizumab plus axitinib — a first-line immunotherapy and targeted-therapy combination for advanced RCC.
-
Palliative and supportive care
Symptom control, bone-targeted therapy and specialist palliative-care input alongside active treatment.
What this guide is based on
The sources behind every number on this page.
UK and European guidance, specialist society standards and patient-organisation resources, current at the time of last review.
Key references
Guidelines and standards we relied on.
A quiet reminder
This guide is for information, not medical advice.
Your GP or uro-oncology team knows your history and can tell you which parts apply to you.
-
National Institute for Health and Care Excellence (NICE). Kidney cancer guidance.
-
European Association of Urology (EAU). Guidelines on renal cell carcinoma.
-
Kidney Cancer UK. Patient information and support.
-
International Kidney Cancer Coalition (IKCC). Global patient resources.
Red flags
When kidney cancer becomes an emergency.
Most of the time, kidney cancer is treated to a plan. These are the situations where you should act today rather than wait for a routine appointment.
-
Massive haematuria with clot retention
Visible blood with an inability to pass urine — same-day urology assessment or A&E.
-
Tumour thrombus into the IVC
Tumour extension into the inferior vena cava needs urgent specialist vascular and surgical planning.
-
Neutropenic sepsis
Fever after systemic therapy — call the 24-hour oncology hotline or attend A&E immediately.
-
Immune-mediated adrenal insufficiency
Fatigue, dizziness and low sodium on checkpoint immunotherapy — needs urgent bloods and steroids.
-
Post-nephrectomy renal impairment
A rising creatinine after kidney surgery needs prompt review to protect the remaining kidney.
-
Post-transplant renal cancer
A new renal mass in a transplant kidney or native kidney of a transplant recipient needs specialist referral.
-
Familial syndrome cascade
A VHL or HLRCC diagnosis in the family should trigger genetic counselling for first-degree relatives.
-
Bone metastases with fracture risk
Severe or worsening bone pain in known RCC — urgent imaging to assess fracture risk and treatment.
-
Palliative-stage crisis
Uncontrolled pain, breathlessness or bleeding in advanced disease — contact your specialist team the same day.
Living with it
A long-term journey, with structured support.
Four things that make the biggest difference day to day — monitoring, kidney health, immunotherapy side effects and specialist follow-up.
A quiet reminder
Flag new symptoms early.
On checkpoint immunotherapy, new tiredness, bowel change, breathlessness or dizziness needs early review — most side effects are treatable when caught quickly.
- 01 Monitoring
Surveillance imaging matters
After treatment, structured CT follow-up over years is how recurrences are picked up early enough to act on.
- 02 Kidney health
Protecting the remaining kidney
Blood pressure control, avoiding nephrotoxic drugs and hydration all help preserve long-term kidney function.
- 03 Side effects
Immunotherapy side effects
Checkpoint inhibitors can affect the thyroid, adrenals, bowel and skin — flag new symptoms early to your team.
- 04 Reviews
Structured follow-up
Regular uro-oncology follow-up with imaging and bloods, tailored to your risk group, keeps things on track.
Frequently asked
Everything we get asked about kidney cancer.
Quick answers on diagnosis, active surveillance, partial nephrectomy, immunotherapy and inherited kidney cancers.
-
What is kidney cancer?
Kidney cancer most often means renal cell carcinoma (RCC), a cancer arising from the lining of the small tubes inside the kidney. Clear cell RCC is the most common subtype.
-
How is kidney cancer usually found?
Most renal cell carcinomas are detected incidentally on a scan done for another reason. Classical symptoms — blood in the urine, flank pain, a lump — are the exception rather than the rule.
-
What is active surveillance for a small renal mass?
For small renal masses — usually under 4 cm — regular imaging can be a safe alternative to surgery, particularly in older adults or those with other health problems. Many small masses grow very slowly.
-
Why is partial nephrectomy preferred?
Removing only the tumour and preserving the rest of the kidney protects long-term kidney function, which matters for cardiovascular and overall health. It is chosen wherever it is technically feasible.
-
What is combination immunotherapy for advanced kidney cancer?
For advanced RCC, first-line treatment is usually a combination — either two immunotherapy drugs (ipilimumab plus nivolumab), or an immunotherapy plus a targeted drug (pembrolizumab plus axitinib). These combinations have transformed outcomes.
-
Is kidney cancer inherited?
Most kidney cancers are sporadic, but familial syndromes exist — including von Hippel-Lindau (VHL) disease and hereditary leiomyomatosis and renal cell cancer (HLRCC). Young age, bilateral tumours or a suggestive family history should prompt genetic referral.
Related content
Keep reading.
-
Abdominal CT
The primary imaging test that characterises and stages a renal mass.
Learn more -
Ultrasound
Often the first scan to spot a renal lesion — quick, radiation-free and widely used.
Learn more -
Kidney function tests
Bloods and urine tests that measure how well your kidneys are working.
Learn more -
All conditions
Browse the full Pulse Atlas library of clinically reviewed guides.
Learn more